Evaluation of the Pharmacokinetics of Curcumin Capsules in Healthy Human

NCT07379177 | Not Yet Recruiting

• 1 other identifier: [2026]Ethical Audit No. (001)
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

Main objective: Through blood drug concentration testing, evaluate the post-meal pharmacokinetic characteristics of the curcumin product compared to similar products, and assess the differences in body exposure between the self-developed product and the control product in healthy trial participants. Secondary objective: Observe the safety of the self-developed product and the control product in healthy trial participants. Study population: Healthy male individuals or non-pregnant non-lactating females

Conditions

Healthy

Keywords

curcumin

Outcome Measures

Primary Outcomes (3)

• Area under the plasma concentration versus time curve (AUC) 0-t

  plasma concentration-time curve from zero to the time of the last measurable time point t

  2 weeks

• Peak Plasma Concentration (Cmax)

  Evaluation of Peak Plasma Concentration (Cmax)

  2 weeks

• Area under the plasma concentration versus time curve (AUC)0-∞

  area under the plasma concentration-time curve from zero to infinity

  2 weeks

Study Arms (2)

Nano Curcumin Capsules

EXPERIMENTAL

Test Group

Dietary Supplement: Nanocurcumin

Curcumin Capsules

ACTIVE COMPARATOR

Reference Group

Dietary Supplement: Curcumin

Interventions

Curcumin DIETARY_SUPPLEMENT

In the first cycle, take 4 capsules of the self-developed product (T, Nano Curcumin Capsules) (125 mg per capsule), in the second cycle take 2 capsules of the control product (R, Curcumin Capsules) (250 mg per capsule), take with 240 mL of water, and the cleansing period is 7 days.

Curcumin Capsules

Nanocurcumin DIETARY_SUPPLEMENT

In the first cycle, take 2 capsules (250mg each) of the control product (R, Curcumin Capsules). In the second cycle, take 4 capsules (125mg each) of the self-developed product (T, Nano Curcumin Capsules). Take with 240 mL of water and the cleansing period is 7 days.

Nano Curcumin Capsules

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Both men and women are eligible; women must be non-pregnant and non-lactating.
• Healthy trial participants aged 18 to 65 years (inclusive of the threshold value).
• Body Mass Index (BMI) = weight (kg) / height² (m²), with BMI within the range of 18.5 to 30.0 kg/m² (including the threshold value); male trial participants must have a weight of ≥ 50.0 kg, and female trial participants must have a weight of ≥ 45.0 kg.
• Voluntary participants who have signed the informed consent form; the process of obtaining the informed consent form complies with GCP.
• Female trial participants agree to use effective non-pharmacological methods for appropriate contraception 2 weeks before the trial diet (for male trial participants, starting from the first trial diet), and within 3 months after the last trial diet, and have no plans for egg donation (male sperm donation).

You may not qualify if:

• Select those who have abnormal and clinically significant findings in physical examination, vital sign examination, blood routine, blood biochemistry, coagulation function, blood pregnancy test (only for females), urine routine, 12-lead electrocardiogram, HBsAg, HCV antibody, HIV antibody, syphilis screening, etc.;
• Those with a history of serious diseases in cardiovascular, endocrine, digestive, respiratory, urinary, immune system and nervous system, or those who developed the above-mentioned diseases during the screening period, and whose research doctors consider them unsuitable to participate in the clinical trial;
• Those who are allergic to two or more drugs or foods (including lactose-intolerant individuals); or those who are prone to asthma, rash, urticaria, etc.; or those who have a known history of allergy to curcumin or any excipients;
• Those with a history of mental illness, drug abuse history, or drug dependence history;
• Those who have used any prescription drugs, over-the-counter drugs, herbal medicine or health supplements within 14 days before the first trial meal (excluding topical preparations or local drug preparations);
• Those who have smoked an average of more than 5 cigarettes per day within the previous 3 months;
• Those who have difficulty in blood collection or cannot tolerate venipuncture blood collection;
• Those who have a history of heavy drinking (more than 14 units of alcohol per day, 1 unit = 360 mL beer or 45 mL 40% spirituous alcohol or 150 mL wine) or who do not agree to stop consuming alcoholic products during the trial period (from the screening day to the last cycle discharge);
• Those who have used drugs within the previous 3 months, or those with a positive drug abuse screening result;
• Those who have consumed excessive tea, coffee or caffeine-containing beverages (more than 8 cups, 1 cup = 250 mL) every day within the previous 3 months;
• Those who have donated blood or suffered massive blood loss (more than 200 mL) within the previous 3 months;
• Those who participated in any drug clinical trial and used any clinical trial drugs within the previous 3 months;
• Those with special dietary requirements and cannot follow the unified diet;
• Those who have taken special diets or other diets that affect drug absorption, distribution, metabolism, and excretion factors within 7 days before the first trial meal;
• Those who have had acute diseases during the screening stage or before the allocation of the trial number;

Sponsors & Collaborators

• Kingdomway (Inner Mongolia) Nutritional Food Co., Ltd.: lead

Study Sites (1)

No. 55, Zhenhai Road

Xiamen, Fujian, 361022, China

Location

MeSH Terms

Interventions

Curcumin; nanocurcumin

Intervention Hierarchy (Ancestors)

Diarylheptanoids; Heptanes; Alkanes; Hydrocarbons, Acyclic; Hydrocarbons; Organic Chemicals; Catechols; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic

Central Study Contacts

Qiyue Liu

CONTACT

86-15952401034; qiyue.liu@cxpharma.com

Lu Ye

CONTACT

86-13950049562; lbe_yl@accube.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 23, 2026
• First Posted: January 30, 2026
• Study Start: January 28, 2026
• Primary Completion: February 7, 2026
• Study Completion: February 28, 2026
• Last Updated: January 30, 2026

Record last verified: 2026-01

Locations

CN (1)